January 5, 2017 — Monaco Growth Forums by Andreea Porcelli announced today that distinguished Comprehensive Cancer Centers of Nevada (CCCN) oncologist and Clinical Associate Professor of the University of Nevada School of Medicine, Dr. Fadi Braiteh, will serve as the keynote speaker at the forum’s gala on March 30th in Napa Valley.

Dr. Braiteh’s presentation, titled “Immuno-oncology: A Leap Forward to Making Cancer a Curable Disease,” will shed light on how cancer treatment has evolved as well as the most recent innovations in the field of immunotherapy – a method of treatment that empowers the patient’s immune system to combat aberrant, harmful cancerous cells.

Dr. Braiteh will join esteemed philanthropists and executives vested in the field of cancer immunotherapy to increase support and awareness of the treatment option. Dr. Braiteh directs CCCN’s Translational Oncology Program (TOP-Phase 1), in collaboration with the US Oncology Research Network, and leads the development of novel anti-cancer agents, many of which are being used in humans for the very first time.

“It is a transformative time in healthcare and at the heart of many of these exciting headlines and developments is immunotherapy,” said Dr. Braiteh. “I look forward to sharing my unique, firsthand experiences pertaining to this new era in cancer treatment with Monaco Growth Forum attendees and hope my insight can inspire positive action in their everyday lives.”

Among Dr. Braiteh’s numerous clinical trials, he participated in the conduction of immunotherapy compound agents including Nivolumab, Pembrolizumab, Avelumab, Durvalumab, Atezolizumab, Ipilumab, Temilumab as well as others in earlier stage of development. Temilumab is being developed to treat several sub-types of cancer such as lung, triple negative breast, bladder and other hematological malignancies. CCCN was originally one of only six centers in the U.S. for “first in-human” testing and, in 2014, the Food and Drug Administration (FDA) named it a “breakthrough therapy” in bladder and lung cancers. Dr. Braiteh’s clinical research has been published in peer- reviewed journals such as Nature, Lancet, Lancet Oncology and Journal of Clinical Oncology, the official publication of the American Society of Clinical Oncology.

CCCN participates in more than 170 Phase I, II and III clinical research studies each year and, to date, its doctors have helped develop more than 60 FDA-approved cancer therapies. Approximately 2,000 out-of- state patients traveled to Southern Nevada for access to CCCN’s world-class treatment and clinical trials in 2015.

X